Article

Combining pharmacogenetics and patient characteristic polygenic scores to improve outcome prediction for Calcium Channel Blocker treatment

2023-02-14

Abstract excerpt

<h4>Background</h4> Calcium channel blockers (CCBs) are common antihypertensive medications. Pharmacogenetic variants affect CCB clinical outcomes, although effect sizes are modest in community samples. Variation in patient characteristics may also predict CCB outcomes, and variation attributable to relevant polygenic scores is less prone to confounding. We aimed to test associations between genetically predicted...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6c603430-4ffc-59fd-87df-e89e970cb3b7
DOI: 10.1101/2023.02.10.23285767

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combining pharmacogenetics and patient characteristic polygenic scores to improve outcome prediction for Calcium Channel Blocker treatmentDOI 10.1101/2023.02.10.23285767Read

Calcium Channel Blockers: clinical outcome associations with reported pharmacogenetics variants in 32,000 patientsSemantic proximity Read

Genetic variants related to antihypertensive targets inform drug efficacy and side effectsSemantic proximity Read

Separating the genetics of disease, treatment and treatment response using graphical modeling and large-scale electronic health recordsSemantic proximity Read

Use of Genetic Variants Related to Antihypertensive Drugs to Inform on Efficacy and Side EffectsSemantic proximity Read

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medicationsSemantic proximity Read

Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.Semantic proximity Read

Genetically predicted blood pressure, antihypertensive drugs and risk of heart failure: a Mendelian randomization study.Semantic proximity Read

RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment.Semantic proximity Read

Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.Semantic proximity Read

Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatmentSemantic proximity Read

Triangulating Evidence for Antihypertensive Drug Class Efficacy on Cardiovascular and Metabolic Outcomes Using Mendelian Randomisation and ColocalisationSemantic proximity Read

Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation studySemantic proximity Read